From the Research Unit for General Practice, Aarhus, Denmark (A.R.R., C.H.V., M.V., H.S.P., A.P., M.F.-G.).
Department of Public Health, Aarhus University, Denmark (M.V., M.F.-G.).
Stroke. 2020 Apr;51(4):1111-1119. doi: 10.1161/STROKEAHA.119.027301. Epub 2020 Mar 2.
Background and Purpose- It has been suggested that statins increase the risk of intracerebral hemorrhage in individuals with a history of stroke, which has led to a precautionary principle of avoiding statins in patients with prior intracerebral hemorrhage. However, such prescribing reticence may be unfounded and potentially harmful when considering the well-established benefits of statins. This study is so far the largest to explore the statin-associated risk of intracerebral hemorrhage in individuals with prior stroke. Methods- We conducted a population-based, propensity score-matched cohort study using information from Danish national registers. We included all individuals initiating statin treatment after a first-time stroke diagnosis (intracerebral hemorrhage, N=2728 or ischemic stroke, N=52 964) during 2002 to 2016. For up to 10 years of follow-up, they were compared with a 1:5 propensity score-matched group of statin nonusers with the same type of first-time stroke. The difference between groups was measured by adjusted hazard ratios for intracerebral hemorrhage calculated by type of first-time stroke as a function of time since statin initiation. Results- Within the study period, 118 new intracerebral hemorrhages occurred among statin users with prior intracerebral hemorrhage and 319 new intracerebral hemorrhages in users with prior ischemic stroke. The risk of intracerebral hemorrhage was similar for statin users and nonusers when evaluated among those with prior intracerebral hemorrhage, and it was reduced by half in those with prior ischemic stroke. These findings were consistent over time since statin initiation and could not be explained by concomitant initiation of other medications, by dilution of treatment effect (due to changes in exposure status over time), or by healthy initiator bias. Conclusions- This large study found no evidence that statins increase the risk of intracerebral hemorrhage in individuals with prior stroke; perhaps the risk is even lower in the subgroup of individuals with prior ischemic stroke.
背景与目的-有研究表明,他汀类药物会增加有中风病史的个体发生脑出血的风险,这导致了在有既往脑出血病史的患者中避免使用他汀类药物的预防原则。然而,考虑到他汀类药物的既定益处,这种谨慎的处方可能是没有依据的,而且可能是有害的。本研究是迄今为止规模最大的一项探索他汀类药物与既往中风患者脑出血风险相关性的研究。
方法-我们使用丹麦国家登记处的信息进行了一项基于人群的、倾向评分匹配队列研究。我们纳入了在 2002 年至 2016 年期间首次中风(脑出血,N=2728 例或缺血性中风,N=52964 例)后开始使用他汀类药物治疗的所有患者。在长达 10 年的随访期间,他们与首次中风类型相同的、按倾向评分匹配的 1:5 他汀类药物未使用者组进行了比较。脑出血的差异通过按他汀类药物起始时间计算的首次中风类型的调整后风险比来衡量。
结果-在研究期间,在既往有脑出血的他汀类药物使用者中,有 118 例新发生脑出血,在既往有缺血性中风的他汀类药物使用者中,有 319 例新发生脑出血。在评估既往有脑出血的患者时,他汀类药物使用者与未使用者的脑出血风险相似,而在既往有缺血性中风的患者中,脑出血风险降低了一半。这些发现随着他汀类药物起始时间的推移而保持一致,不能用同时开始使用其他药物、治疗效果的稀释(由于暴露状态随时间的变化)或健康起始者偏差来解释。
结论-这项大型研究没有发现证据表明他汀类药物会增加既往中风患者发生脑出血的风险;在既往有缺血性中风的患者亚组中,风险甚至可能更低。